Key facts
- It has raised $41.0M; the latest was Later Stage VC ($20.6M) in Feb 2026.
- Notable investors include Korea Investment Partners, Korea Development Bank, Shinhan Capital, Partners Investment, Premier Partners — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Mustbio
- ·The full record, as it builds
Funding rounds
No funding rounds for Mustbio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Mustbio
Developer of drugs and therapeutics designed to treat cancer. The company's drugs are made using multi-antibody platform technology, a natural-like asymmetric IgG form that exists in nature, and it is economically feasible due to the high rate of double-antibody formation, enabling healthcare companies to provide treatment for patients with various types of cancer.
- Sector
- Healthcare
- HQ
- Suwon, South Korea
- Founded
- 2021
- Employees
- 17
- Website
- mustbio.com/
- Ownership
- Privately Held (backing)
Mustbio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Mustbio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Mustbio in its N-PORT filings yet. We sweep new filings monthly.